Clinical Study Confirms Effectiveness of Medical Marijuana, Inc.’s RSHO
March 14th, 2017
Feature Stories, News
Cannabidiol (CBD), the main ingredient in Medical Marijuana, Inc.’s (OTC Pink: MJNA) RSHO-X, has been growing in popularity due to its tremendous potential to treat many serious medical conditions. In fact, the cannabinoid has shown promise in treating everything from arthritis to antibiotic resistant infections to schizophrenia. The non-psychoactive nature of the compound also means that it is subject to less regulatory scrutiny than tetrahydrocannabinol (THC) and maybe be provided both over-the-counter and as a prescription.
In this article, we will take a look at the results of a new study that confirms the safety and efficacy of Medical Marijuana Inc. subsidiary HempMeds Mexico’s flagship product, Real Scientific Hemp Oil-X (RSHO-X).
New Clinical Trial
Medical Marijuana recently announced the results of a study evaluating the safety and effectiveness of RSHO-X 5000 for the treatment of Lennox Gastaut Syndrome – a severe form of childhood encephalopathies with high seizure frequency, progressive cognitive impairment, and antiepileptic drug resistance. The condition affects roughly 30,000 individuals in the United States and another 300,000 individuals around the world.
The study found that RSHO-X 5000 reduced motor seizures for 84% of patients, with more than half of participants reporting a better than 75% reduction in seizures. In addition, 17% of patients reported a complete elimination of all seizures. The study also found an 89% improvement in quality of life, like alertness (43%), social interaction (40%) and attention (30%) with no reported adverse side effects to the 5-7mg of CBD per kilogram of bodyweight.
Medical Marijuana has relied on external evidence to support the import of its RSHO products into countries like Brazil, Mexico, and Puerto Rico for specific medical conditions. While there are numerous studies supporting the use of CBDs, clinical studies involving the company’s own RSHO product lines could provide even more support for importation, since mainstream doctors in these countries and territories may be more willing to prescribe the drug.
In Mexico, the company’s HempMeds Mexico subsidiary became the first to receive a COFEPRIS federal government import permit for a cannabis-derived product (RSHO-X) for a medical indication. The company continues to work directly with the government to safety and legally provide access to CBD hemp oil products targeting a wide range of medical conditions including rare forms of epilepsy and pain associated with serious medical conditions.
The company also continues to penetrate other markets around the world. In Brazil, the company’s HempMeds Brazil subsidiary now treats upwards of 1,500 families with epileptic children, according to a recent Dope Magazine piece, as acceptance of CBD as a legitimate medical treatment for a growing number of illnesses continues to grow. Puerto Rico and other areas have followed suit with their own import permits for RSHO products.
Medical Marijuana Inc. (OTC Pink: MJNA) represents a promising investment opportunity within the burgeoning cannabis industry. In addition to its recent clinical validation, the company provides investors with access to many other areas of the market through its extensive portfolio of subsidiaries and investments. These include investments in biotech companies like AXIM Biotechnologies Inc. (OTCQB: AXIM) and wholly-owned sales and marketing arms.
To view the study, click here.
Follow Us on Social Media
About CFN Media
CFN Media (CannabisFN) is the leading creative agency and media network dedicated to legal cannabis. We help marijuana businesses attract investors, customers (B2B, B2C), capital, and media visibility. Private and public marijuana companies and brands in the US and Canada rely on CFN Media to grow and succeed.
CFN launched in June of 2013 to initially serve the growing universe of publicly traded marijuana companies across North America. Today, CFN Media is also the digital media choice for the emerging brands in the space.
Disclaimer: Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Emerging Growth LLC dba TDM Financial, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. Emerging Growth LLC dba TDM Financial, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. Emerging Growth LLC dba TDM Financial, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: http://www.cannabisfn.com/legal-disclaimer/.